JP2006511516A5 - - Google Patents

Download PDF

Info

Publication number
JP2006511516A5
JP2006511516A5 JP2004557217A JP2004557217A JP2006511516A5 JP 2006511516 A5 JP2006511516 A5 JP 2006511516A5 JP 2004557217 A JP2004557217 A JP 2004557217A JP 2004557217 A JP2004557217 A JP 2004557217A JP 2006511516 A5 JP2006511516 A5 JP 2006511516A5
Authority
JP
Japan
Prior art keywords
complementarity determining
region
amino acid
humanized
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2004557217A
Other languages
English (en)
Japanese (ja)
Other versions
JP4773097B2 (ja
JP2006511516A (ja
Filing date
Publication date
Priority claimed from US10/307,276 external-priority patent/US7388079B2/en
Application filed filed Critical
Publication of JP2006511516A publication Critical patent/JP2006511516A/ja
Publication of JP2006511516A5 publication Critical patent/JP2006511516A5/ja
Application granted granted Critical
Publication of JP4773097B2 publication Critical patent/JP4773097B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2004557217A 2002-11-27 2003-11-18 ヒトインスリン受容体を介する医薬品の送達 Expired - Fee Related JP4773097B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/307,276 2002-11-27
US10/307,276 US7388079B2 (en) 2002-11-27 2002-11-27 Delivery of pharmaceutical agents via the human insulin receptor
PCT/US2003/036870 WO2004050016A2 (en) 2002-11-27 2003-11-18 Delivery of pharmaceutical agents via the human insulin receptor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011023913A Division JP5981688B2 (ja) 2002-11-27 2011-02-07 ヒトインスリン受容体を介する医薬品の送達

Publications (3)

Publication Number Publication Date
JP2006511516A JP2006511516A (ja) 2006-04-06
JP2006511516A5 true JP2006511516A5 (enExample) 2010-09-02
JP4773097B2 JP4773097B2 (ja) 2011-09-14

Family

ID=32325847

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2004557217A Expired - Fee Related JP4773097B2 (ja) 2002-11-27 2003-11-18 ヒトインスリン受容体を介する医薬品の送達
JP2011023913A Expired - Fee Related JP5981688B2 (ja) 2002-11-27 2011-02-07 ヒトインスリン受容体を介する医薬品の送達
JP2016014310A Pending JP2016155803A (ja) 2002-11-27 2016-01-28 ヒトインスリン受容体を介する医薬品の送達

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2011023913A Expired - Fee Related JP5981688B2 (ja) 2002-11-27 2011-02-07 ヒトインスリン受容体を介する医薬品の送達
JP2016014310A Pending JP2016155803A (ja) 2002-11-27 2016-01-28 ヒトインスリン受容体を介する医薬品の送達

Country Status (5)

Country Link
US (3) US7388079B2 (enExample)
EP (1) EP1569691B1 (enExample)
JP (3) JP4773097B2 (enExample)
AU (1) AU2003295614A1 (enExample)
WO (1) WO2004050016A2 (enExample)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7388079B2 (en) * 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
US20040102369A1 (en) * 2002-11-27 2004-05-27 The Regents Of The University Of California Transport of basic fibroblast growth factor across the blood brain barrier
ES2368941T3 (es) * 2003-01-06 2011-11-23 Angiochem Inc. Angiopep-1, compuestos relacionados y utilizaciones correspondientes.
EP2902491A1 (en) 2003-03-19 2015-08-05 Biogen MA Inc. NOGO receptor binding protein
EP1460088A1 (en) 2003-03-21 2004-09-22 Biotest AG Humanized anti-CD4 antibody with immunosuppressive properties
AU2003286870A1 (en) * 2003-06-05 2005-01-04 Salk Institute For Biological Studies Targeting polypeptides to the central nervous system
EP1776136B1 (en) 2004-06-24 2012-10-03 Biogen Idec MA Inc. Treatment of conditions involving demyelination
US7659289B2 (en) * 2004-09-17 2010-02-09 Comentis, Inc. Hydroxyethylene-based β-secretase inhibitors and use thereof
AU2005286844A1 (en) * 2004-09-17 2006-03-30 Comentis, Inc Bicyclic compounds which inhibit beta-secretase activity and methods of use thereof
JP2008535863A (ja) * 2005-04-08 2008-09-04 コメンティス，インコーポレーテッド β−セクレターゼ活性を阻害する化合物およびその使用方法
AU2006269458B2 (en) 2005-07-08 2012-11-08 Biogen Ma Inc. Sp35 antibodies and uses thereof
PL2233156T3 (pl) * 2005-07-15 2013-09-30 Angiochem Inc Zastosowanie polipeptydów aprotyninowych jako nośników w koniugatach farmaceutycznych
US8124095B2 (en) 2005-10-07 2012-02-28 Armagen Technologies, Inc. Fusion proteins for delivery of erythropoietin to the CNS
US8142781B2 (en) * 2005-10-07 2012-03-27 Armagen Technologies, Inc. Fusion proteins for blood-brain barrier delivery
US8741260B2 (en) * 2005-10-07 2014-06-03 Armagen Technologies, Inc. Fusion proteins for delivery of GDNF to the CNS
PE20070684A1 (es) * 2005-11-14 2007-08-06 Amgen Inc MOLECULAS QUIMERICAS DE ANTICUERPO RANKL-PTH/PTHrP
EP1981546B1 (en) 2006-02-06 2014-06-04 The Medical Research and Infrastructure Fund of the Tel-Aviv Sourasky Medical Center Enzyme replacement therapy for treating lysosomal storage diseases
US8497246B2 (en) 2006-08-18 2013-07-30 Armagen Technologies, Inc. Methods for diagnosing and treating CNS disorders by trans-blood-brain barrier delivery of protein compositions
US20080200441A1 (en) * 2007-02-14 2008-08-21 University Of Southern California Estrogen receptor modulators associated pharmaceutical compositions and methods of use
US20090011040A1 (en) * 2007-05-02 2009-01-08 Naash Muna I Use of compacted nucleic acid nanoparticles in non-viral treatments of ocular diseases
US9365634B2 (en) * 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
MX2010000956A (es) * 2007-07-26 2010-03-01 Comentis Inc Derivados de isoftalamida que inhiben actividad de beta-secretasa.
JP5901877B2 (ja) * 2007-07-27 2016-04-13 アーメイゲン・テクノロジーズ・インコーポレイテッドＡｒｍａｇｅｎ Ｔｅｃｈｎｏｌｏｇｉｅｓ， Ｉｎｃ． 中枢神経系のα−Ｌ−イデュロニダーゼ活性を増加させるための方法および組成物
CA2699787A1 (en) * 2007-09-24 2009-04-02 Comentis, Inc. (3-hydroxy-4-amino-butan-2-yl)-3-(2-thiazol-2-yl-pyrrolidine-1-carbonyl) benzamide derivatives and related compounds as beta-secretase inhibitors for treating
RU2540018C2 (ru) 2008-03-13 2015-01-27 Биотест Аг Средство для лечения заболевания
CN102027016A (zh) 2008-03-13 2011-04-20 生物测试股份公司 一种治疗疾病的试剂
EP2265643B1 (en) 2008-03-13 2016-10-19 Biotest AG Dosing regimen for treating psoriasis and rheumatoid arthritis
JP5860698B2 (ja) 2008-04-18 2016-02-16 アンジオケム，インコーポレーテッド パクリタキセル、パクリタキセル類似体またはパクリタキセルコンジュゲートの医薬組成物ならびに関連する調製方法および使用方法
WO2009152319A1 (en) * 2008-06-13 2009-12-17 Synvista Therapeutics, Inc. Reagents and methods for detecting a polymorphic protein
DK2982695T3 (da) 2008-07-09 2019-05-13 Biogen Ma Inc Sammensætninger, der omfatter antistoffer mod lingo eller fragmenter deraf
US20100098693A1 (en) * 2008-10-07 2010-04-22 Pardridge William M Compositions and methods for blood-brain barrier delivery of organophosphatases
JP5705118B2 (ja) 2008-10-15 2015-04-22 アンジオケム インコーポレーテッド 薬物送達のためのエトポシドおよびドキソルビシン複合体
EP2346906A4 (en) 2008-10-15 2013-04-24 Angiochem Inc CONJUGATES FROM GLP-1 AGONISTS AND THEIR USE
JP5759379B2 (ja) 2008-12-05 2015-08-05 アンジオケム インコーポレーテッド ニューロテンシンまたはニューロテンシンアナログおよびその使用
WO2010069074A1 (en) 2008-12-17 2010-06-24 Universite Du Quebec A Montreal Membrane type-1 matrix metalloprotein inhibitors and uses thereof
US9533055B2 (en) 2009-03-18 2017-01-03 Armagen Technologies, Inc. Compositions and methods for blood-brain barrier delivery of IgG-decoy receptor fusion proteins
EP2421562B1 (en) 2009-04-20 2019-03-13 Angiochem Inc. Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog
RU2012103240A (ru) 2009-07-02 2013-08-10 Ангиокем Инк. Мультимерные пептидные конъюгаты и их применение
CN102596232A (zh) 2009-08-28 2012-07-18 西奈山医学院 用于治疗酸性鞘磷脂酶缺乏的剂量递增酶替代疗法
US8926976B2 (en) 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
AU2010298036B2 (en) 2009-09-25 2015-05-21 Xoma Technology Ltd. Screening methods
ES2725200T3 (es) 2009-10-09 2019-09-20 Armagen Inc Métodos y composiciones para aumentar la actividad de iduronato 2-sulfatasa en el SNC
US20130079382A1 (en) 2009-10-12 2013-03-28 Larry J. Smith Methods and Compositions for Modulating Gene Expression Using Oligonucleotide Based Drugs Administered in vivo or in vitro
GB0920944D0 (en) 2009-11-30 2010-01-13 Biotest Ag Agents for treating disease
SG186068A1 (en) * 2010-05-27 2013-01-30 Janssen Biotech Inc Insulin-like growth factor 1 receptor binding peptides
EP4338797A3 (en) 2011-12-02 2024-06-12 Armagen, Inc. Methods and compositions for increasing arylsulfatase a activity in the cns
EP2804602B1 (en) 2012-01-20 2024-12-04 Del Mar Pharmaceuticals Use of substituted hexitols including dianhydrogalactitol and analogs to treat neoplastic disease and cancer stem cells including glioblastoma multforme and medulloblastoma
NZ702178A (en) 2012-05-14 2017-01-27 Biogen Ma Inc Lingo-2 antagonists for treatment of conditions involving motor neurons
JP6692293B2 (ja) 2013-07-22 2020-05-13 アーマジェン・インコーポレイテッドＡｒｍａｇｅｎ， Ｉｎｃ． Ｃｎｓにおける酵素活性を増大するための方法および組成物
AU2014368696A1 (en) 2013-12-20 2016-06-02 F. Hoffmann-La Roche Ag Humanized anti-Tau(pS422) antibodies and methods of use
WO2015098989A1 (ja) 2013-12-25 2015-07-02 Ｊｃｒファーマ株式会社 血液脳関門を通過する新規抗トランスフェリン受容体抗体
CA2942152C (en) * 2014-03-06 2023-08-01 National Research Council Of Canada Insulin-like growth factor 1 receptor -specific antibodies and uses thereof
JP6541236B2 (ja) * 2014-03-06 2019-07-10 ナショナル リサーチ カウンシル オブ カナダ インスリン様成長因子１受容体特異的抗体及びそれらの使用
WO2015131257A1 (en) * 2014-03-06 2015-09-11 National Research Council Of Canada Insulin-like growth factor 1 receptor -specific antibodies and uses thereof
TWI731535B (zh) 2014-03-21 2021-06-21 美商艾伯維有限公司 抗-egfr抗體及抗體藥物結合物
CA2946538A1 (en) 2014-04-04 2015-10-08 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
AR100978A1 (es) 2014-06-26 2016-11-16 Hoffmann La Roche LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
WO2016112270A1 (en) 2015-01-08 2016-07-14 Biogen Ma Inc. Lingo-1 antagonists and uses for treatment of demyelinating disorders
US10538589B2 (en) 2015-01-14 2020-01-21 Armagen Inc. Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU
CA2989400A1 (en) 2015-06-15 2016-12-22 Angiochem Inc. Ang1005 for the treatment of leptomeningeal carcinomatosis
CN113929779B (zh) 2015-06-24 2025-02-25 豪夫迈·罗氏有限公司 人源化的抗-Tau(pS422)抗体和使用方法
CA2990565A1 (en) 2015-06-24 2016-12-29 Jcr Pharmaceuticals Co., Ltd. Fusion protein containing bdnf and anti-human transferrin receptor antibody
TWI769982B (zh) 2015-06-24 2022-07-11 日商Ｊｃｒ製藥股份有限公司 通過血腦障壁之抗人類運鐵蛋白受體抗體
US11207461B2 (en) 2015-07-30 2021-12-28 Anoop U. R Drug delivery system and method for controlled and continuous delivery of drugs into the brain by bypassing the blood brain barrier
CA2994841A1 (en) 2015-08-06 2017-02-09 Xoma (Us) Llc Antibody fragments against the insulin receptor and uses thereof to treat hypoglycemia
CN107465528B (zh) * 2016-06-03 2022-04-15 中兴通讯股份有限公司 光分配网络odn资源信息采集方法及装置
JP2019526529A (ja) 2016-06-08 2019-09-19 アッヴィ・インコーポレイテッド 抗ｂ７−ｈ３抗体及び抗体薬物コンジュゲート
AU2017277914A1 (en) 2016-06-08 2019-01-03 Abbvie Inc. Anti-CD98 antibodies and antibody drug conjugates
CN107474136B (zh) * 2016-06-08 2023-03-07 上海交通大学医学院 增强激动型抗体活性的抗体重链恒定区序列
RS61828B1 (sr) 2016-06-08 2021-06-30 Abbvie Inc Anti-b7-h3 antitela i antitelske konjugacije lekova
CN109641962A (zh) 2016-06-08 2019-04-16 艾伯维公司 抗b7-h3抗体和抗体药物偶联物
JP7350313B2 (ja) 2016-12-16 2023-09-26 ブルーフィン バイオメディシン， インコーポレイテッド 抗ｃｕｂドメイン含有タンパク質１（ｃｄｃｐ１）抗体、抗体薬物コンジュゲート、およびその使用方法
CN109983031B (zh) 2016-12-26 2022-11-25 Jcr制药股份有限公司 通过血脑屏障的新的抗人转铁蛋白受体抗体
KR102573622B1 (ko) 2016-12-26 2023-08-31 제이씨알 파마 가부시키가이샤 Bdnf를 포함하는 융합 단백질
EP3612567B1 (en) 2017-04-19 2024-09-11 Bluefin Biomedicine, Inc. Anti-vtcn1 antibodies and antibody drug conjugates
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
JP7657440B2 (ja) 2017-06-12 2025-04-07 ブルーフィン バイオメディシン， インコーポレイテッド 抗－ｉｌ１ｒａｐ抗体および抗体薬物コンジュゲート
WO2019023056A1 (en) * 2017-07-24 2019-01-31 Janssen Biotech, Inc. INSULIN RECEPTOR ANTIBODIES AND USES THEREOF
MA50746A (fr) 2017-10-02 2020-08-12 Denali Therapeutics Inc Protéines de fusion comprenant des enzymes d'enzymothérapie substitutive
EP3898689A1 (en) 2018-12-20 2021-10-27 Armagen, Inc. Purification of iduronate-2-sulfatase immunoglobulin fusion protein
AR124681A1 (es) 2021-01-20 2023-04-26 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
JP2023159049A (ja) 2022-04-19 2023-10-31 Ｊｃｒファーマ株式会社 マンノース－６－リン酸の数を減少させた糖蛋白質
WO2025027529A1 (en) 2023-07-31 2025-02-06 Advesya Anti-il-1rap antibody drug conjugates and methods of use thereof
WO2025126157A1 (en) 2023-12-15 2025-06-19 Advesya Anti-il-1rap binding domains and antibody-drug conjugates thereof
WO2025171378A1 (en) 2024-02-09 2025-08-14 Rezolute, Inc. Insulin receptor modulation for tumor associated hyperinsulinism

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US4801575A (en) * 1986-07-30 1989-01-31 The Regents Of The University Of California Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4902505A (en) * 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5229500A (en) * 1989-08-30 1993-07-20 Regeneron Pharmaceuticals, Inc. Brain derived neurotrophic factor
US5180820A (en) * 1989-08-30 1993-01-19 Barde Yves Alain Brain-derived neurotrophic factor
US5672683A (en) * 1989-09-07 1997-09-30 Alkermes, Inc. Transferrin neuropharmaceutical agent fusion protein
US5154924A (en) * 1989-09-07 1992-10-13 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
US5977307A (en) * 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
US6329508B1 (en) * 1989-09-07 2001-12-11 Alkermes, Inc. Transferrin receptor reactive chimeric antibodies
TW279133B (enExample) * 1990-12-13 1996-06-21 Elan Med Tech
US5527288A (en) * 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
US6060069A (en) * 1991-05-20 2000-05-09 Dura Pharmaceuticals, Inc. Pulmonary delivery of pharmaceuticals
US6287792B1 (en) * 1991-06-17 2001-09-11 The Regents Of The University Of California Drug delivery of antisense oligonucleotides and peptides to tissues in vivo and to cells using avidin-biotin technology
CA2119463C (en) * 1991-09-20 2003-09-16 Leu-Fen H. Lin Glial cell line-derived neutrophic factor
AU677216B2 (en) * 1992-07-27 1997-04-17 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Targeting of liposomes to the blood-brain barrier
US5527228A (en) * 1993-05-24 1996-06-18 Atomic Energy Corporation Of South Africa Limited Transmission
US5997501A (en) * 1993-11-18 1999-12-07 Elan Corporation, Plc Intradermal drug delivery device
ATE208633T1 (de) * 1994-09-16 2001-11-15 Merck Patent Gmbh Immunokonjugate
US5656284A (en) * 1995-04-24 1997-08-12 Balkin; Michael S. Oral transmucosal delivery tablet and method of making it
AU6163196A (en) * 1995-06-07 1996-12-30 Smithkline Beecham Corporation Method for obtaining receptor agonist antibodies
ES2326705T3 (es) * 1995-09-14 2009-10-16 Virginia Tech Intellectual Properties, Inc. Produccion de enzimas lisosomicas en sistemas de expresion basados en plantas.
WO1997010806A1 (en) * 1995-09-19 1997-03-27 Fujisawa Pharmaceutical Co., Ltd. Aerosol compositions
US5837231A (en) * 1996-06-27 1998-11-17 Regents Of The University Of Minnesota GM-CSF administration for the treatment and prevention of recurrence of brain tumors
DK0941344T3 (da) 1996-11-27 2004-09-27 Genentech Inc Humaniserede anti-CD11a-antistoffer
IL120485A0 (en) * 1997-03-19 1997-07-13 Yeda Res & Dev Modulators of the function of receptors of the TNF/NGF receptor family and other proteins
WO1999000150A2 (en) 1997-06-27 1999-01-07 Regents Of The University Of California Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor
US6482923B1 (en) 1997-09-17 2002-11-19 Human Genome Sciences, Inc. Interleukin 17-like receptor protein
US6165783A (en) * 1997-10-24 2000-12-26 Neuro Spheres Holdings Ltd. Erythropoietin-mediated neurogenesis
US6016800A (en) * 1997-10-24 2000-01-25 Century; Theodore J. Intrapulmonary aerosolizer
US6905686B1 (en) * 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
ATE406935T1 (de) * 1997-12-11 2008-09-15 Alza Corp Vorrichtung zur verbesserung des transdermalen flusses von medikamenten
US6348210B1 (en) * 1998-11-13 2002-02-19 Alza Corporation Methods for transdermal drug administration
US6375975B1 (en) * 1998-12-21 2002-04-23 Generex Pharmaceuticals Incorporated Pharmaceutical compositions for buccal and pulmonary application
US6284262B1 (en) * 1999-01-26 2001-09-04 Virgil A. Place Compact dosage unit for buccal administration of a pharmacologically active agent
US7410941B1 (en) * 1999-04-13 2008-08-12 The Kenneth S. Warren Institute, Inc. Methods for treatment of neurodegenerative conditions by peripherally administered erythropoietin
CZ299516B6 (cs) * 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
US6372250B1 (en) * 2000-04-25 2002-04-16 The Regents Of The University Of California Non-invasive gene targeting to the brain
US6696274B2 (en) * 2000-05-03 2004-02-24 Supratek Pharma, Inc. Ligand for enhancing oral and CNS delivery of biological agents
US7078376B1 (en) * 2000-08-11 2006-07-18 Baxter Healthcare S.A. Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects
US20030165853A1 (en) * 2000-12-04 2003-09-04 The Regents Of The University Of California Office Of Technology Transfer Antisense imaging of gene expression of the brain in vivo
WO2002064085A2 (en) * 2001-02-02 2002-08-22 Ortho-Mcneil Pharmaceutical, Inc. Treatment of neurological dysfunction comprising fructopyranose sulfamates and erythropoietin
RU2003125637A (ru) * 2001-02-06 2005-03-10 Мерк Патент ГмбХ (DE) Модифицированный нейтрофический фактор выделенный из мозга человека (bdnf) с уменьшенной иммуногенностью
IL166244A0 (en) * 2001-07-12 2006-01-15 Jefferson Foote Super humanized antibodies
EP2147679B1 (en) * 2001-07-25 2014-06-25 Raptor Pharmaceutical, Inc. Compositions for blood-brain barrier transport
US7053202B2 (en) * 2001-10-19 2006-05-30 Millennium Pharmaceuticals, Inc. Immunoglobulin DNA cassette molecules, monobody constructs, methods of production, and methods of use therefor
NZ571508A (en) * 2002-05-24 2010-05-28 Schering Corp Neutralizing human anti-IGFR antibody
US20050142141A1 (en) * 2002-11-27 2005-06-30 Pardridge William M. Delivery of enzymes to the brain
US7388079B2 (en) * 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
US20040102369A1 (en) * 2002-11-27 2004-05-27 The Regents Of The University Of California Transport of basic fibroblast growth factor across the blood brain barrier
US7294704B2 (en) * 2003-08-15 2007-11-13 Diadexus, Inc. Pro108 antibody compositions and methods of use and use of Pro108 to assess cancer risk
EP1548031A1 (en) * 2003-12-22 2005-06-29 Dubai Genetics FZ-LLC Nature-identical erythropoietin
US8142781B2 (en) * 2005-10-07 2012-03-27 Armagen Technologies, Inc. Fusion proteins for blood-brain barrier delivery
US8124095B2 (en) * 2005-10-07 2012-02-28 Armagen Technologies, Inc. Fusion proteins for delivery of erythropoietin to the CNS
US8741260B2 (en) * 2005-10-07 2014-06-03 Armagen Technologies, Inc. Fusion proteins for delivery of GDNF to the CNS
DE102006004008A1 (de) * 2006-01-27 2007-08-02 Hannelore Prof. Dr. Dr. Ehrenreich Verfahren zur Behandlung und/oder Prophylaxe von Multipler Sklerose, sowie Verwendung von Erythropoietin zur Herstellung eines Arzneimittels zur intermittierenden Behandlung und/oder intermittierenden Prophylaxe von Multipler Sklerose
KR101248252B1 (ko) * 2006-11-28 2013-03-27 한올바이오파마주식회사 변형된 에리스로포이에틴 폴리펩티드와 이의 치료용 용도
EP2167115A2 (en) * 2007-06-15 2010-03-31 University Of Zurich Treatment for alzheimer's disease

Similar Documents

Publication Publication Date Title
JP2006511516A5 (enExample)
US10882909B2 (en) Antigen binding constructs to CD3
JP6964631B2 (ja) Ｃｄ４７に対するヒト化及びキメラモノクローナル抗体
AU2018214223B2 (en) Low pH pharmaceutical composition comprising T cell engaging antibody constructs
CN108136012B (zh) 靶向分子的抗原结合构建体
US20220144943A1 (en) Anti-cd47 antibodies and uses thereof
JP2011509245A5 (enExample)
Li et al. Natural single-domain antibody-nanobody: a novel concept in the antibody field
CN104105708A (zh) PDGF受体β结合多肽
JP2011501656A5 (enExample)
KR20230016186A (ko) 갈렉틱-3 차단에 의한 염증성 질환의 치료 방법
JP2025183307A5 (enExample)
HRP20171580T1 (hr) Ljudska monoklonska protutijela koja su specifična za protein e denga virusa serotipa 1 i njihova upotreba
JP2019537617A5 (enExample)
JP2021509668A (ja) 免疫抑制なしにｉｌ−６媒介性炎症を処置する方法
JP2008521426A5 (enExample)
JP2006506450A (ja) 粥状動脈硬化の治療用のペプチドベースの受動免疫療法
EP4615867A1 (en) Methods for the treatment of cardiovascular disease
JP2025522962A (ja) 抗体並びにそれを作製及び使用する方法
JP2003513985A (ja) 天然に存在しないエナンチオマー（Ｌ−ビオチン）を結合する抗体および該抗体のターゲッティング薬剤（ａｇｅｎｔ）としての使用
JP2018531625A5 (enExample)
WO2022060878A1 (en) Methods for treating prostate cancer
WO2004100882A3 (en) Inhibition of drug binding to serum albumin
JPWO2019228514A5 (enExample)
CN119768431A (zh) Igf1r抗体